CYT 004 MelQbG10

Drug Profile

CYT 004 MelQbG10

Alternative Names: CYT004-MelQbG10; Melan-A VLP vaccine - Cytos; Melanoma virus-like particle vaccine - Cytos

Latest Information Update: 31 Aug 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytos Biotechnology
  • Class Cancer vaccines; Virus-like particle vaccines
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 01 Jul 2010 Cytos Biotechnology completes a phase II trial in Malignant melanoma in Switzerland
  • 24 Feb 2009 Phase II development is ongoing in Switzerland
  • 22 Nov 2007 Interim immunogenicity, adverse event and efficacy data from three phase IIa trials in malignant melanoma released by Cytos Biotechnology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top